

## FROM BIOMARKERS TO INNOVATIVE THERAPIES IN HIGH-RISK CANCERS

8:30	<b>Registration</b>
	<b>Session 1 – Next-generation therapies in oncology &amp; hematology</b>
8:45	<b>The saga of therapeutic antibody development in cancer*</b> Prof. Daniel Olive, professor of immunology, head of the Immunity and Cancer team, Cancer Research Center of Marseille
9:30	<b>Engage them! Efficacy and mechanisms of action of bispecific antibodies in immunotherapies</b> Prof. Cyrille Touzeau, hematologist, CHU Nantes — Dr. Nils Giordano, postdoctoral researcher, CRCI <sup>2</sup> NA — Dr. Catherine Pellat-Deceunynck, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI <sup>2</sup> NA
10:10	<b>Breaking tumour resistance with the rise of targeted therapies: from scientific innovation to medical application</b> Prof. Benoît Tessoulin, hematologist, CHU Nantes — Dr. David Chiron, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI <sup>2</sup> NA
10:40	<b>Break</b>
10:55	<b>CAR-T cells in brain tumours</b> Dr. Claire Pecqueur, head of the Petry team, CRCI <sup>2</sup> NA — Dr. Béatrice Clémenceau, research engineer in Manipulation of Lymphocytes for Immunotherapy team, CRCI <sup>2</sup> NA
	<b>Session 2 – Theranostics &amp; targeted radionuclide therapies</b>
11:25	<b>Shaping the future of glioblastoma treatment: locoregional At-211 radiotherapy targeting Syndecan-1 leads durable remission &amp; immune memory</b> Dr. Emmanuel Garcion, head of the Innovative local alternatives in the medical treatment of glioblastoma team, CRCI <sup>2</sup> NA
11:40	<b>Prospects for radiotheranostics in prostate cancer</b> Dr. Clément Bailly, nuclear physician, CHU Nantes — Prof. Stéphane Supiot, radiation oncologist, ICO — Prof. Jérôme Rigaud, head of the urology department, CHU Nantes
12:20	<b>Targeting CXCR4 in hematological diseases</b> Prof. Caroline Bodet-Milin, nuclear physician, CHU Nantes
12:30	<b>Lunch</b>
14:00	<b>Radioligand therapy and breast cancer: challenges and new horizons*</b> Prof. Désirée Deandreis, chief of the nuclear medicine division, Institut Gustave Roussy
	<b>Session 3 – Imaging &amp; AI-driven biomarker discovery</b>
14:40	<b>Interest of machine learning in PET for hematologic malignancies: from early developments to today</b> Dr. Thomas Carlier, medical physicist in nuclear medicine, CHU de Nantes — Oriane Thierry, PhD student LS2N
15:10	<b>Using predictive models in radiotherapy: towards personalised medicine</b> Dr. Tanguy Perennec, radiation oncologist, head of artificial intelligence unit, ICO
15:30	<b>Break</b>
	<b>Session 4 – Biomarkers &amp; therapy response: new Insights in oncology &amp; hematology</b>
15:45	<b>FLT3-Ligand and IL-6: impact on acute leukemia management</b> Prof. Joëlle Gaschet, nuclear oncology team, CRCI <sup>2</sup> NA, Nantes Université — Dr. Pierre Peterlin, hematologist, CHU Nantes
16:15	<b>Epigenetic/Epitranscriptomic biomarkers in lung cancer therapy</b> Dr. Judith Raimbourg, medical oncologist, ICO — Dr. Pierre François Cartron, researcher in Stress Adaptation and Tumor Escape team, CRCI <sup>2</sup> NA / ICO
16:45	<b>EV-Score as a biomarker: exploration of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment</b> Prof. Jean-Sébastien Frenel, medical oncologist, ICO — Dr. Laetitia Guével, Signaling in Oncogenesis, Angiogenesis and Permeability team, CRCI <sup>2</sup> NA, Nantes Université
17:15	<b>End of the conference</b>

\* visioconference presentation

Organisé par :

